Imugene Ltd (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$21.41 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
557.27 million
Earnings per share
-0.320
Dividend per share
N/A
Year To Date Return
-89.32%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Ltd (ASX: IMU)
Latest News
Cheap Shares
6 ASX shares down 50%+ in 2024. Are they cheap?
Share Gainers
Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher
Share Gainers
Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher
ASX Share Market News
Guess which ASX 300 stock is jumping 11% on big news
Healthcare Shares
2 All Ords ASX healthcare shares making BIG moves on quarterly updates
Share Fallers
Why AGL, Imugene, Star, and Woolworths shares are dropping today
Share Gainers
Why Appen, Cettire, DroneShield, and Imugene shares are racing higher
Healthcare Shares
Why this ASX All Ords stock is soaring 30% on Monday
Share Gainers
Why Catalyst Metals, Imugene, Red 5, and Telstra shares are pushing higher today
Share Gainers
2 ASX shares roaring higher on big news
Healthcare Shares
3 ASX healthcare shares outperforming on quarterly updates
Healthcare Shares
Broker says this ASX biotech stock could almost double in value
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imugene Ltd
Imugene Ltd (ASX: IMU) is a clinical-stage immuno-oncology company developing therapies that harness the immune system to treat cancer.
Its lead asset is azer-cel, an off-the-shelf allogeneic CAR T-cell therapy targeting CD19 to treat blood cancers, currently in Phase 1b trials. The company's broader pipeline includes the CF33 oncolytic virus platform and B-cell immunotherapy candidates such as HER-Vaxx and PD1-Vaxx.
IMU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Oct 2026 | $0.04 | $0.00 | 0.00% | 1,833,594 | $0.04 | $0.04 | $0.04 |
| 08 Oct 2026 | $0.04 | $0.00 | 0.00% | 2,315,349 | $0.04 | $0.04 | $0.04 |
| 07 Oct 2026 | $0.04 | $0.00 | 0.00% | 4,284,215 | $0.04 | $0.04 | $0.04 |
| 06 Oct 2026 | $0.04 | $0.00 | 0.00% | 3,986,611 | $0.05 | $0.05 | $0.04 |
| 05 Oct 2026 | $0.04 | $0.01 | 27.03% | 19,537,971 | $0.04 | $0.05 | $0.04 |
| 02 Oct 2026 | $0.04 | $0.00 | 0.00% | 5,400,451 | $0.04 | $0.04 | $0.04 |
| 01 Oct 2026 | $0.04 | $0.00 | 0.00% | 5,211,887 | $0.04 | $0.04 | $0.04 |
| 30 Sep 2026 | $0.04 | $0.00 | 0.00% | 1,683,385 | $0.04 | $0.04 | $0.04 |
| 29 Sep 2026 | $0.04 | $0.00 | 0.00% | 1,048,439 | $0.04 | $0.04 | $0.04 |
| 28 Sep 2026 | $0.04 | $0.00 | 0.00% | 1,767,094 | $0.05 | $0.05 | $0.04 |
| 25 Sep 2026 | $0.04 | $0.00 | 0.00% | 2,229,255 | $0.04 | $0.04 | $0.04 |
| 24 Sep 2026 | $0.04 | $0.00 | 0.00% | 2,162,405 | $0.04 | $0.05 | $0.04 |
| 23 Sep 2026 | $0.04 | $0.00 | 0.00% | 3,479,990 | $0.05 | $0.05 | $0.04 |
| 22 Sep 2026 | $0.05 | $0.00 | 0.00% | 2,093,399 | $0.05 | $0.05 | $0.05 |
| 21 Sep 2026 | $0.05 | $0.00 | 0.00% | 2,229,871 | $0.05 | $0.05 | $0.05 |
| 18 Sep 2026 | $0.05 | $0.00 | 0.00% | 1,983,282 | $0.05 | $0.05 | $0.05 |
| 17 Sep 2026 | $0.05 | $0.00 | 0.00% | 3,910,667 | $0.05 | $0.05 | $0.05 |
| 16 Sep 2026 | $0.05 | $0.00 | 0.00% | 3,473,324 | $0.05 | $0.05 | $0.05 |
| 15 Sep 2026 | $0.05 | $-0.01 | -18.87% | 6,238,952 | $0.05 | $0.05 | $0.05 |
| 14 Sep 2026 | $0.05 | $0.00 | 0.00% | 3,786,265 | $0.06 | $0.06 | $0.05 |
| 11 Sep 2026 | $0.05 | $0.00 | 0.00% | 3,206,030 | $0.06 | $0.06 | $0.05 |
| 10 Sep 2026 | $0.06 | $0.00 | 0.00% | 2,370,473 | $0.06 | $0.06 | $0.06 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 29 Sep 2026 | Jakob Dupont | Exercise | 50,001 | $2,150 |
Options expired.
|
| 31 Aug 2026 | Kim Drapkin | Expiry | 3,502 | $238 |
Options expired.
|
| 31 Aug 2026 | Lesley Russell | Expiry | 7,003 | $476 |
Options expired.
|
| 31 Aug 2026 | Jakob Dupont | Expiry | 2,627 | $178 |
Options expired. As per announcement 01-09-26
|
| 31 Aug 2026 | Paul Hopper | Expiry | 85,785 | $5,833 |
Options expired.
|
| 25 Aug 2026 | Paul Hopper | Buy | 947,369 | $90,000 |
Placement.
|
| 01 Jul 2026 | Lesley Russell | Exercise | 7,353 | $1,029 |
Conversion of securities. 80,882 RSUs
|
| 01 Jul 2026 | Lesley Russell | Buy | 7,353 | $1,029 |
Conversion of securities.
|
| 01 Jul 2026 | Jakob Dupont | Exercise | 7,353 | $1,029 |
Conversion of securities. 80,882 RSUs
|
| 01 Jul 2026 | Jakob Dupont | Issued | 7,353 | $1,029 |
Conversion of securities.
|
| 01 Jul 2026 | Kim Drapkin | Buy | 7,353 | $1,029 |
Conversion of securities.
|
| 01 Jul 2026 | Kim Drapkin | Exercise | 7,353 | $1,029 |
Conversion of securities. 80,882 RSUs
|
| 30 Jun 2026 | Jakob Dupont | Expiry | 11,764 | $1,352 |
Options expired. As per announcement
|
| 30 Jun 2026 | Lesley Russell | Expiry | 17,648 | $2,029 |
Options expired.
|
| 30 Jun 2026 | Leslie (Mi Ok) Chong | Expiry | 508,824 | $58,514 |
Options expired.
|
| 30 Jun 2026 | Paul Hopper | Expiry | 85,295 | $9,808 |
Options expired.
|
| 14 May 2026 | Paul Hopper | Buy | 180,000 | $18,648 |
On-market trade.
|
| 14 May 2026 | Leslie (Mi Ok) Chong | Buy | 355,164 | $36,404 |
On-market trade.
|
| 11 May 2026 | Leslie (Mi Ok) Chong | Buy | 230,285 | $24,755 |
On-market trade.
|
| 16 Apr 2026 | Leslie (Mi Ok) Chong | Buy | 65,053 | $9,432 |
On-market trade.
|
| 17 Dec 2025 | Lesley Russell | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 17 Dec 2025 | Lesley Russell | Exercise | 14,706 | $4,705 |
Conversion of securities. 88,235 RSU
|
| 17 Dec 2025 | Jakob Dupont | Exercise | 14,706 | $4,705 |
Conversion of securities. 88235 RSU
|
| 17 Dec 2025 | Jakob Dupont | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 17 Dec 2025 | Kim Drapkin | Exercise | 14,706 | $4,705 |
Conversion of securities. 88,235 RSU
|
| 17 Dec 2025 | Kim Drapkin | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 15 Dec 2025 | Kim Drapkin | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 1,02,941 RSU
|
| 15 Dec 2025 | Jakob Dupont | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 102941 RSU
|
| 15 Dec 2025 | Lesley Russell | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 1,02,941 RSU
|
| 15 Dec 2025 | Leslie (Mi Ok) Chong | Issued | 751,621 | $236,760 |
Employee Share Ownership Plan. 1,518,441 Rights
|
| 15 Dec 2025 | Paul Hopper | Issued | 124,054 | $39,077 |
Employee Share Ownership Plan. 260,320 rights, As per announcement on 19-12-2025
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Alex Hopper | Executive ChairmanExecutive Director | Dec 2013 |
Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies in Australia and the United States. Experience includes immunotherapy and capital markets.
|
| Mr Michael John Kotsanis | Non-Executive Director | Jun 2026 |
Mr Kotsanis has 35 years of experience in global pharmaceutical markets, with experience in regional operations, commercialisation, licensing and market expansion.
|
| Dr Lesley Russell | Non-Executive Director | Apr 2019 |
Dr Russell has over 25 years' experience in the international pharmaceutical field, with experience in leadership roles and multiple new drug approvals with the FDA and EMA. Dr Russell is a member of Risk Committee.
|
| Dr Charmaine Hilary Gittleson | Non-Executive Director | Jun 2026 |
Dr Gittleson has over 20 years of global experience in drug development, clinical strategy and regulatory affairs.
|
| Dr Jakob Dupont | Non-Executive Director | Sep 2022 |
Dr Dupont has more than 20 years of experience in drug development, specialising in oncology, including experience with Sofinnova Investments. He is a member of the Risk Committee.
|
| Ms Kim Drapkin | Non-Executive Director | Jun 2023 |
Ms Drapkin Has over 25 years of experience with private and publicly traded biotechnology and pharmaceutical companies, including building finance functions, raising capital and strategic financial planning.
|
| Mr Darren Keamy | Chief Financial OfficerCompany Secretary | Mar 2025 |
-
|
| Darren Keamy | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr John Byon | Other Corporate Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 31,735,765 | 6.47% |
| JP Morgan Nominees Australia Pty Limited | 23,627,085 | 4.82% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 19,389,235 | 3.95% |
| HSBC Custody Nominees (Australia) Limited | 15,155,836 | 3.09% |
| Precision Biosciences Inc | 11,816,141 | 2.41% |
| BNP Paribas Noms Pty Ltd | 9,289,987 | 1.89% |
| Buttonwood Nominees Pty Ltd | 8,152,047 | 1.66% |
| BNP Paribas Noms (NZ) Ltd | 7,502,374 | 1.53% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 7,041,966 | 1.44% |
| Moreglade Pty Ltd | 5,573,541 | 1.14% |
| Miss Mi Ok Chong | 3,940,003 | 0.80% |
| Moreglade Pty Ltd (i) | 3,739,002 | 0.76% |
| Dr Nicholas Smith | 3,470,589 | 0.71% |
| Merrill Lynch (Australia) Nominees Pty Limited | 3,309,835 | 0.67% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> | 3,273,218 | 0.67% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 3,266,314 | 0.67% |
| Mr Richard John Mann | 3,205,883 | 0.65% |
| Mr Victor Mark Coppleson | 2,897,428 | 0.59% |
| Netwealth Investments Limited <Wrap Services A/C> | 2,813,892 | 0.57% |
| Mann Beef Pty Ltd | 2,764,706 | 0.56% |
